/DISREGARD RELEASE: Jiangsu Vcare/
View all comments(0)
We are advised by Jiangsu Vcare that journalists and other readers should disregard the news release, Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA, issued 04-Jan-2024 over PR Newswire.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Nvidia Q3 Revenue Surges 103%, Next-Quarter Revenue Guidance Reaches $130 Billion, Shares Briefly Rise Over 4% After Hours

Today’s Market Recap: Three Major US Indexes Tumble, Broadcom and Arm Buck Trend, Nvidia Earnings Beat Expectations

【US Pre-Market】Nvidia Rises Nearly 1% Ahead of Post-Market Earnings as US Tightens AI Chip Remote Access Restrictions

Nvidia Stock Price Forecast: Ahead of Q3 Earnings, Options Market Implies 8.5% Swing, Will It Hit $168 or $141?

Nvidia Beats by $7 Billion in Its First Quarter Without Huang, but NVDA Must Hold $149.13






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.